Lv54
940 积分 2023-11-27 加入
(ENCORE) Rinatabart sesutecan for patients with advanced ovarian cancer: Results from dose expansion cohort B1 of phase I/II study
1天前
已完结
PART C OF RAINFOL™-01: A PHASE 1/2 STUDY OF SINGLE-AGENT RINATABART SESUTECAN IN PATIENTS WITH ADVANCED AND/OR METASTATIC PLATINUM-RESISTANT OVARIAN CANCER
1天前
已关闭
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
1天前
已完结
Abstract GS1-09: OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer:
3天前
已关闭
Pharmacological Parameters and Pharmacokinetic Variability Derived from Bioequivalence Trials in a Mexican Population
6天前
已完结
晚期卵巢上皮性癌患者NACT+IDS治疗模式的预后获益及影响因素分析
6天前
已完结
New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer
7天前
已完结
Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance
7天前
已完结
Advances in cervical cancer: current insights and future directions
9天前
已完结
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
14天前
已完结
皖公网安备34019202002308
